Loading company…
Suzhou-based biopharma developing RNAi oligonucleotide drugs for cardiovascular, metabolic, renal and liver diseases.
Suzhou Ribo Life Science Co., Ltd. was founded in 2007 in Suzhou, China. It develops oligonucleotide drugs based on RNA interference, including RBD4059 for thrombotic diseases and RBD1016 for chronic hepatitis B. The company received clinical trial approval for a metastatic prostate cancer drug in August 2020. In January 2026 it raised HKD 1.83 billion in a Hong Kong IPO under ticker 6938. Stage: Series E.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in